The mutations of KRAS and TP53, inactivation of p16/CDKN2A, and SMAD4/DPC4 in PanIN, IPMN, and MCN were found in the analysis of FFPE samples of tumor tissues [50]. This evidence concerns the gene CDKN2A and neoplasm.